{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:32:17Z","timestamp":1787729537225,"version":"build-2784847793"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s13555-025-01377-3","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T11:27:02Z","timestamp":1742729222000},"page":"1009-1024","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treating Generalized Pustular Psoriasis (GPP): Timing and Rationale for Biologic Treatment Switching\u2014A Japanese e-Delphi Survey"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3743-135X","authenticated-orcid":false,"given":"Yayoi","family":"Tada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Imafuku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumitsu","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Tsuruta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruyuki","family":"Mitsuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Yoshizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukie","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akimichi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,22]]},"reference":[{"key":"1377_CR1","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1111\/1346-8138.14523","volume":"45","author":"H Fujita","year":"2018","unstructured":"Fujita H, Terui T, Hayama K, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP. J Dermatol. 2018;45:1235\u201370.","journal-title":"J Dermatol"},{"key":"1377_CR2","first-page":"669","volume":"16","author":"F Augey","year":"2006","unstructured":"Augey F, Renaudier P, Nicolas J-F. Generalized pustular psoriasis (Zumbusch): a French epidemiological survey. Eur J Dermatol. 2006;16:669\u201373.","journal-title":"Eur J Dermatol"},{"key":"1377_CR3","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/ijd.12070","volume":"53","author":"SE Choon","year":"2014","unstructured":"Choon SE, Lai NM, Mohammad NA, Nanu NM, Tey KE, Chew SF. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor. Malaysia Int J Dermatol. 2014;53:676\u201384.","journal-title":"Malaysia Int J Dermatol"},{"key":"1377_CR4","doi-asserted-by":"publisher","first-page":"68","DOI":"10.2340\/00015555766871","volume":"76","author":"A Ohkawara","year":"1996","unstructured":"Ohkawara A, Yasuda H, Kobayashi H et al. Generalized pustular psoriasis in Japan: two distinct groups formed by differences in symptoms and genetic background. Acta Derm Venereol. 1996;76:68\u201371.","journal-title":"Acta Derm Venereol"},{"key":"1377_CR5","doi-asserted-by":"publisher","first-page":"761","DOI":"10.5021\/ad.2017.29.6.761","volume":"29","author":"JY Lee","year":"2017","unstructured":"Lee JY, Kang S, Park JS, Jo SJ. Prevalence of psoriasis in Korea: a population-based epidemiological study using the Korean national health insurance database. Ann Dermatol. 2017;29:761\u20137.","journal-title":"Ann Dermatol"},{"key":"1377_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40257-021-00663-y","volume":"23","author":"DV Reisner","year":"2022","unstructured":"Reisner DV, Johnsson FD, Kotowsky N, Brunette S, Valdecantos W, Eyerich K. Impact of generalized pustular psoriasis from the perspective of people living with the condition: results of an online survey. Am J Clin Dermatol. 2022;23:65\u201371.","journal-title":"Am J Clin Dermatol"},{"key":"1377_CR7","doi-asserted-by":"crossref","unstructured":"Romiti R, Hirayama AL da S, Arnone M, Magalh\u00e3es RF. Generalized pustular psoriasis (von Zumbusch). An Bras Dermatol. 2022;97:63\u201374.","DOI":"10.1016\/j.abd.2021.05.011"},{"key":"1377_CR8","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1111\/exd.14794","volume":"32","author":"SE Choon","year":"2023","unstructured":"Choon SE, Elewski BE, Fujita H et al. Diversity in the clinical presentation of generalized pustular psoriasis (GPP): a series of case vignettes from around the world. Exp Dermatol. 2023;32:1284\u201395.","journal-title":"Exp Dermatol"},{"key":"1377_CR9","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.jaad.2021.06.008","volume":"86","author":"H Miyachi","year":"2022","unstructured":"Miyachi H, Konishi T, Kumazawa R et al. Treatments and outcomes of generalized pustular psoriasis: A cohort of 1516 patients in a nationwide inpatient database in Japan. J Am Acad Dermatol. 2022;86:1266\u201374.","journal-title":"J Am Acad Dermatol"},{"key":"1377_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40257-021-00654-z","volume":"23","author":"SE Choon","year":"2022","unstructured":"Choon SE, Navarini AA, Pinter A. Clinical course and characteristics of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23:21\u20139.","journal-title":"Am J Clin Dermatol"},{"key":"1377_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40257-021-00658-9","volume":"23","author":"J Krueger","year":"2022","unstructured":"Krueger J, Puig L, Tha\u00e7i D. Treatment options and goals for patients with generalized pustular psoriasis. Am J Clin Dermatol. 2022;23:51\u201364.","journal-title":"Am J Clin Dermatol"},{"key":"1377_CR12","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/1346-8138.14294","volume":"45","author":"S Sano","year":"2018","unstructured":"Sano S, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study. J Dermatol. 2018;45:529\u201339.","journal-title":"J Dermatol"},{"key":"1377_CR13","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s13555-021-00666-x","volume":"12","author":"A Morita","year":"2022","unstructured":"Morita A, Okubo Y, Morisaki Y, Torisu-Itakura H, Umezawa Y. Ixekizumab 80 mg every 2 weeks treatment beyond week 12 for Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis. Dermatol Ther (Heidelb). 2022;12:481\u201394.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1377_CR14","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1111\/1346-8138.14664","volume":"45","author":"A Morita","year":"2018","unstructured":"Morita A, Yamazaki F, Matsuyama T et al. Adalimumab treatment in Japanese patients with generalized pustular psoriasis: results of an open-label phase 3 study. J Dermatol. 2018;45:1371\u201380.","journal-title":"J Dermatol"},{"key":"1377_CR15","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/1346-8138.13306","volume":"43","author":"S Imafuku","year":"2016","unstructured":"Imafuku S, Honma M, Okubo Y et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol. 2016;43:1011\u20137.","journal-title":"J Dermatol"},{"key":"1377_CR16","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1056\/NEJMoa1013068","volume":"365","author":"S Marrakchi","year":"2011","unstructured":"Marrakchi S, Guigue P, Renshaw BR et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365:620\u20138.","journal-title":"N Engl J Med"},{"key":"1377_CR17","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.ajhg.2011.07.022","volume":"89","author":"A Onoufriadis","year":"2011","unstructured":"Onoufriadis A, Simpson MA, Pink AE et al. Mutations in IL36RN\/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet. 2011;89:432\u20137.","journal-title":"Am J Hum Genet"},{"key":"1377_CR18","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa2111563","volume":"385","author":"H Bachelez","year":"2021","unstructured":"Bachelez H, Choon S-E, Marrakchi S et al. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021;385:2431\u201340.","journal-title":"N Engl J Med"},{"key":"1377_CR19","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(23)01378-8","volume":"402","author":"A Morita","year":"2023","unstructured":"Morita A, Strober B, Burden AD et al. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial. Lancet. 2023;402:1541\u201351.","journal-title":"Lancet"},{"key":"1377_CR20","unstructured":"Boehringer-Ingelheim. European Commission approves SPEVIGO\u00ae for new and expanded indications in generalized pustular psoriasis. 2024. https:\/\/www.boehringer-ingelheim.com\/human-health\/european-commission-approves-spevigo-new-and-expanded-indications-generalized-pustular-psoriasis. Accessed 14 Jan 2025."},{"key":"1377_CR21","unstructured":"Boehringer-Ingelheim. SPEVIGO approved for expanded indications in China and the US. 2024. https:\/\/www.boehringer-ingelheim.com\/us\/human-health\/skin-and-inflammatory-diseases\/gpp\/spevigo-approved-expanded-indications-china-and-us. Accessed 25 July 2025"},{"key":"1377_CR22","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/j.jid.2019.11.024","volume":"140","author":"S Frey","year":"2020","unstructured":"Frey S, Sticht H, Wilsmann-Theis D et al. Rare loss-of-function mutation in SERPINA3 in generalized pustular psoriasis. J Invest Dermatol. 2020;140:1451-1455.e13.","journal-title":"J Invest Dermatol"},{"key":"1377_CR23","doi-asserted-by":"publisher","first-page":"e439","DOI":"10.1111\/1346-8138.16530","volume":"49","author":"K Hayama","year":"2022","unstructured":"Hayama K, Fujita H, Terui T. Current trend in the treatment of generalized pustular psoriasis in Japan: results from a questionnaire-based epidemiological study. J Dermatol. 2022;49:e439\u201340.","journal-title":"J Dermatol"},{"key":"1377_CR24","unstructured":"UCB S.A. CIMZIA\u00ae (certolizumab pegol) now available for patients in Japan living with multiple psoriatic diseases https:\/\/www.ucb.com\/stories-media\/Press-Releases\/article\/CIMZIA-certolizumab-pegol-now-Available-for-Patients-in-Japan-living-with-Multiple-Psoriatic-Diseases. Accessed 20 Feb 2024."},{"key":"1377_CR25","unstructured":"UCB S.A. BIMZELX[\u00ae] (bimekizumab) approved in Japan for the treatment of plaque psoriasis, generalized pustular psoriasis and psoriatic erythroderma. https:\/\/www.ucb.com\/stories-media\/Press-Releases\/article\/BIMZELXR-bimekizumab-Approved-in-Japan-for-the-Treatment-of-Plaque-Psoriasis-Generalized-Pustular-Psoriasis-and-Psoriatic-Erythroderma. Accessed 20 Feb 2024."},{"key":"1377_CR26","unstructured":"Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labour and Welfare. Guselkumab (genetical recombination) approval review report. https:\/\/www.pmda.go.jp\/files\/000234741.pdf. Accessed 20 Feb 2024."},{"key":"1377_CR27","unstructured":"Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labour and Welfare. Risankizumab (genetical recombination) approval review report. https:\/\/www.pmda.go.jp\/files\/000239461.pdf. Accessed 20 Feb 2024."},{"key":"1377_CR28","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40262-019-00829-2","volume":"59","author":"AA Suleiman","year":"2020","unstructured":"Suleiman AA, Khatri A, Oberoi RK, Othman AA. Exposure-response relationships for the efficacy and safety of risankizumab in Japanese subjects with psoriasis. Clin Pharmacokinet. 2020;59:575\u201389.","journal-title":"Clin Pharmacokinet"},{"key":"1377_CR29","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1007\/s40265-022-01801-4","volume":"82","author":"HA Blair","year":"2022","unstructured":"Blair HA. Spesolimab: first approval. Drugs. 2022;82:1681\u20136.","journal-title":"Drugs"},{"key":"1377_CR30","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1111\/1346-8138.16084","volume":"48","author":"Y Okubo","year":"2021","unstructured":"Okubo Y, Kotowsky N, Gao R, Saito K, Morita A. Clinical characteristics and health-care resource utilization in patients with generalized pustular psoriasis using real-world evidence from the Japanese Medical Data Center database. J Dermatol. 2021;48:1675\u201387.","journal-title":"J Dermatol"},{"key":"1377_CR31","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1111\/1346-8138.16022","volume":"48","author":"A Morita","year":"2021","unstructured":"Morita A, Kotowsky N, Gao R, Shimizu R, Okubo Y. Patient characteristics and burden of disease in Japanese patients with generalized pustular psoriasis: results from the Medical Data Vision claims database. J Dermatol. 2021;48:1463\u201373.","journal-title":"J Dermatol"},{"key":"1377_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-008048","volume":"5","author":"A Page","year":"2015","unstructured":"Page A, Potter K, Clifford R, McLachlan A, Etherton-Beer C. Prescribing for Australians living with dementia: study protocol using the Delphi technique. BMJ Open. 2015;5: e008048.","journal-title":"BMJ Open"},{"key":"1377_CR33","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1177\/0269216317690685","volume":"31","author":"S J\u00fcnger","year":"2017","unstructured":"J\u00fcnger S, Payne SA, Brine J, Radbruch L, Brearley SG. Guidance on conducting and REporting DElphi studies (CREDES) in palliative care: recommendations based on a methodological systematic review. Palliat Med. 2017;31:684\u2013706.","journal-title":"Palliat Med"},{"key":"1377_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s41073-022-00122-0","volume":"7","author":"WT Gattrell","year":"2022","unstructured":"Gattrell WT, Hungin AP, Price A et al. ACCORD guideline for reporting consensus-based methods in biomedical research and clinical practice: a study protocol. Res Integr Peer Rev. 2022;7:3.","journal-title":"Res Integr Peer Rev"},{"key":"1377_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-065154","volume":"12","author":"EJ van Zuuren","year":"2022","unstructured":"van Zuuren EJ, Logullo P, Price A, Fedorowicz Z, Hughes EL, Gattrell WT. Existing guidance on reporting of consensus methodology: a systematic review to inform ACCORD guideline development. BMJ Open. 2022;12: e065154.","journal-title":"BMJ Open"},{"key":"1377_CR36","unstructured":"Beiderbeck D, Frevel N, Gracht HA von der, Schmidt SL, Schweitzer VM. Preparing, conducting, and analyzing Delphi surveys: Cross-disciplinary practices, new directions, and advancements. Methods X. 2021. https:\/\/methods-x.com\/article\/S2215-0161(21)00194-1\/fulltext. Accessed 24 Jan 2024."},{"key":"1377_CR37","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12874-020-01029-4","volume":"20","author":"R Veugelers","year":"2020","unstructured":"Veugelers R, Gaakeer MI, Patka P, Huijsman R. Improving design choices in Delphi studies in medicine: the case of an exemplary physician multi-round panel study with 100% response. BMC Med Res Methodol. 2020;20:156.","journal-title":"BMC Med Res Methodol"},{"key":"1377_CR38","first-page":"1","volume":"2","author":"D Fink-Hafner","year":"2019","unstructured":"Fink-Hafner D, Dagen T, Dou\u0161ak M, Novak M, Hafner-Fink M. Delphi method: strengths and weaknesses. Adv Methodol Stat. 2019;2:1\u201319.","journal-title":"Adv Methodol Stat"},{"key":"1377_CR39","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40268-017-0215-7","volume":"17","author":"L Costa","year":"2017","unstructured":"Costa L, Perricone C, Chimenti MS et al. Switching between biological treatments in psoriatic arthritis: a review of the evidence. Drugs R D. 2017;17:509\u201322.","journal-title":"Drugs R D"},{"key":"1377_CR40","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/1346-8138.14834","volume":"46","author":"B Bayaraa","year":"2019","unstructured":"Bayaraa B, Imafuku S. Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka University Psoriasis Registry. J Dermatol. 2019;46:389\u201398.","journal-title":"J Dermatol"},{"key":"1377_CR41","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.det.2007.01.010","volume":"25","author":"JA Zeichner","year":"2007","unstructured":"Zeichner JA, Lebwohl M. Potential complications associated with the use of biologic agents for psoriasis. Dermatol Clin. 2007;25:207-13 vii.","journal-title":"Dermatol Clin"},{"key":"1377_CR42","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1111\/jdv.15600","volume":"33","author":"DP de la Cueva","year":"2019","unstructured":"de la Cueva DP, Notario J, Ferr\u00e1ndiz C, L\u00f3pez Estebaranz JL, Alarc\u00f3n I, Sulleiro S, et al. Expert consensus on the persistence of biological treatments in moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol. 2019;33:1214\u201323.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1377_CR43","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/1346-8138.15146","volume":"47","author":"M Kishimoto","year":"2020","unstructured":"Kishimoto M, Komine M, Kamiya K, Sugai J, Mieno M, Ohtsuki M. Drug survival of biologic agents for psoriatic patients in a real-world setting in Japan. J Dermatol. 2020;47:33\u201340.","journal-title":"J Dermatol"},{"key":"1377_CR44","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1111\/1346-8138.13860","volume":"44","author":"H Honda","year":"2017","unstructured":"Honda H, Umezawa Y, Kikuchi S et al. Switching of biologics in psoriasis: reasons and results. J Dermatol. 2017;44:1015\u20139.","journal-title":"J Dermatol"},{"key":"1377_CR45","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1136\/ard.2007.082925","volume":"67","author":"LC Coates","year":"2008","unstructured":"Coates LC, Cawkwell LS, Ng NWF et al. Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience. Ann Rheum Dis. 2008;67:717\u20139.","journal-title":"Ann Rheum Dis"},{"key":"1377_CR46","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14704","volume":"34","author":"A Polat Ekinci","year":"2021","unstructured":"Polat Ekinci A, B\u00f6l\u00fck KN, Babuna KG. Secukinumab and acitretin as a combination therapy for three clinical forms of severe psoriasis in multi-drug refractory patients: a case series of high efficacy and safety profile. Dermatol Ther. 2021;34: e14704.","journal-title":"Dermatol Ther"},{"key":"1377_CR47","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/jdv.18851","volume":"37","author":"L Puig","year":"2023","unstructured":"Puig L, Choon SE, Gottlieb AB et al. Generalized pustular psoriasis: a global Delphi consensus on clinical course, diagnosis, treatment goals and disease management. J Eur Acad Dermatol Venereol. 2023;37:737\u201352.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1377_CR48","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMc1811317","volume":"380","author":"H Bachelez","year":"2019","unstructured":"Bachelez H, Choon S-E, Marrakchi S et al. Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis. N Engl J Med. 2019;380:981\u20133.","journal-title":"N Engl J Med"},{"key":"1377_CR49","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1016\/j.ajpath.2015.07.006","volume":"185","author":"G K\u00f5ks","year":"2015","unstructured":"K\u00f5ks G, Uudelepp M-L, Limbach M, Peterson P, Reimann E, K\u00f5ks S. Smoking-induced expression of the GPR15 gene indicates its potential role in chronic inflammatory pathologies. Am J Pathol. 2015;185:2898\u2013906.","journal-title":"Am J Pathol"},{"key":"1377_CR50","doi-asserted-by":"publisher","first-page":"e437","DOI":"10.1111\/jdv.19678","volume":"38","author":"F Bellinato","year":"2024","unstructured":"Bellinato F, Gisondi P, Dattola A et al. Spesolimab in patients with flare of generalized pustular psoriasis: a multicentre case-series. J Eur Acad Dermatol Venereol. 2024;38:e437\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1377_CR51","doi-asserted-by":"publisher","first-page":"2334791","DOI":"10.1080\/09546634.2024.2334791","volume":"35","author":"C Yang","year":"2024","unstructured":"Yang C, Wang Y, Li R, Tu P, Wang R. Successful treatment of recalcitrant generalized pustular psoriasis of pregnancy with spesolimab. J Dermatol Treat. 2024;35:2334791.","journal-title":"J Dermatol Treat"},{"key":"1377_CR52","doi-asserted-by":"publisher","first-page":"98","DOI":"10.4103\/ds.DS-D-24-00070","volume":"42","author":"C-K Hsu","year":"2024","unstructured":"Hsu C-K, Huang Y-H, Chang C-H et al. Taiwanese dermatological association consensus recommendations for the diagnosis, treatment, and management of generalized pustular psoriasis. Dermatol Sin. 2024;42:98.","journal-title":"Dermatol Sin"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01377-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01377-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01377-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T03:59:27Z","timestamp":1743911967000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01377-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,22]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1377"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01377-3","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,22]]},"assertion":[{"value":"26 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yayoi Tada has received grants, consultancy\/speaker's honoraria, and honoraria as an advisory board member from Boehringer Ingelheim. Shinichi Imafuku has received grants from AbbVie, Eisai, Kyowa Kirin, Taiho Pharmaceutical, Mitsubishi Tanabe, Tsumura, Torii Pharmaceutical, Maruho, LEO Pharma, Sun Pharmaceutical Industries, Kaken, Nippon Zoki Pharmaceutical, Sato Pharmaceutical, Eli Lilly, and Sanofi; received consulting activities fees from Meiji Seika Pharma, Bristol Myers Squibb, JT, LEO Pharma, Boehringer Ingelheim, Pfizer, Maruho, and UCB; received speaker\u2019s honoraria from Astellas Pharma, AbbVie, Eli Lilly, Otsuka Pharmaceutical, Kaken, Kyowa Kirin, Sato Pharmaceutical, Sanofi, Sun Pharmaceutical Industries, GSK, Amgen, Daiichi Sankyo, Takeda Pharmaceutical, Taiho Pharmaceutical, Mitsubishi Tanabe, Tsumura, Torii Pharmaceutical, Nippon Zoki Pharmaceutical, Novartis, Pfizer, Bristol Myers Squibb, Maruho, LEO Pharma, Janssen, and UCB; and received honoraria as an advisory board member from Kyowa Kirin, Pfizer, LEO Pharma, AbbVie, Bristol Myers Squibb, and Boehringer Ingelheim. Kazumitsu Sugiura has received grants from AbbVie, Eli Lilly, Maruho, Taiho Pharmaceutical, Eisai, Kyowa Kirin, and Boehringer Ingelheim; received consulting fees from AbbVie, Janssen, Boehringer Ingelheim, Eli Lilly, and LEO Pharma; received speaker\u2019s honoraria from AbbVie, Eisai, Janssen, LEO Pharma, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Kyowa Kirin, Maruho, Novartis, Taiho Pharmaceutical, Torii Pharmaceutical, and UCB; and received support for attending meetings and\/or travel from AbbVie, Janssen, Boehringer Ingelheim, Eli Lilly, Kyowa Kirin, Novartis, Taiho Pharmaceutical, and UCB. Hideki Fujita has received grants from Maruho, Taiho, Torii Pharmaceutical, Kaken, Eisai, Kyowa Kirin, and Sun Pharmaceutical Industries; received consultancy\/speaker's honoraria from Boehringer Ingelheim, AbbVie, LEO Pharma, Taiho Pharmaceutical, Amgen, Eisai, Eli Lilly, Janssen, JMEC, Kyowa Kirin, Maruho, Mitsubishi Tanabe, Novartis, Sun Pharmaceutical Industries, Taiho Pharmaceutical, Torii Pharmaceutical, UCB, Ushio, and Bristol Myers Squibb; and received honoraria as an advisory board member from Boehringer Ingelheim, AbbVie, LEO Pharma, Sun Pharmaceutical Industries, UCB. Noriko Tsuruta has received consulting fees from Boehringer Ingelheim. Teruyuki Mitsuma has nothing to disclose. Ayumi Yoshizaki has received speaker\u2019s honoraria and payment for expert testimony from Boehringer Ingelheim. Masatoshi Abe has received speaker\u2019s honoraria from Taiho Pharmaceutical, Sanofi, Maruho, Eli Lilly, Amgen, AbbVie, Torii Pharmaceutical, Kyowa Kirin, and Novartis. Yukie Yamaguchi has received grants from Maruho, Taiho Pharmaceutical, Sun Pharmaceutical Industries, Kyowa Kirin, Eli Lilly, Mitsubishi Tanabe, and Torii Pharmaceutical; received consulting honoraria from UCB, LEO Pharma, Taiho Pharmaceutical, and Boehringer Ingelheim; and received speaker\u2019s honoraria from UCB, Eli Lilly, Janssen, Amgen, LEO Pharma, Mitsubishi Tanabe, Bristol Myers Squibb, Taiho Pharmaceutical, AbbVie, Kyowa Kirin, Novartis, and Sun Pharmaceutical Industries. Akimichi Morita has received grants from AbbVie, Kyowa Kirin, LEO Pharma, Maruho, Torii Pharmaceutical, Taiho Pharmaceutical, Mitsubishi Tanabe, Sun Pharmaceutical Industries, and Eisai; received consulting honoraria from Boehringer Ingelheim, Novartis, AbbVie, Nichi-Iko, and Nippon Kayaku; received speaker\u2019s honoraria from AbbVie, Eli Lilly, Eisai, Janssen, Kyowa Kirin, Maruho, Mitsubishi Tanabe, Pfizer, Sun Pharmaceutical Industries, Torii Pharmaceutical, UCB, Taiho Pharmaceutical, and Novartis; and received honoraria as an advisory board member from Bristol Myers Squibb, GSK, Eli Lilly, Kyowa Kirin, Pfizer, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This type of study does not require any patient information, hence no ethical review or approval was necessary. The study utilized data from anonymized experts\u2019 answers, and all experts involved in the e-Delphi were included as authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}